The first quarter of 2018 report of Jianfeng Group
Release time:
2021-01-05
公司代码:600668 公司简称:尖峰集团
浙江尖峰集团股份有限公司
2018年第一季度报告正文
一、 重要提示
1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
1.2 公司全体董事出席董事会审议季度报告。
1.3 公司负责人蒋晓萌、主管会计工作负责人兰小龙及会计机构负责人(会计主管人员)吴德富保证季度报告中财务报表的真实、准确、完整。
1.4 本公司第一季度报告未经审计。
二、 公司主要财务数据和股东变化
2.1 主要财务数据
单位:元 币种:人民币
|
|
本报告期末 |
上年度末 |
本报告期末比上年度末增减(%) |
|
总资产 |
4,366,775,455.41 |
4,175,730,846.73 |
4.58 |
|
归属于上市公司股东的净资产 |
2,757,802,176.89 |
2,627,318,888.65 |
4.97 |
|
|
年初至报告期末 |
上年初至上年报告期末 |
比上年同期增减(%) |
|
经营活动产生的现金流量净额 |
13,967,176.23 |
317,755.25 |
4,295.58 |
|
|
年初至报告期末 |
上年初至上年报告期末 |
比上年同期增减(%) |
|
营业收入 |
669,522,008.06 |
566,846,953.96 |
18.11 |
|
归属于上市公司股东的净利润 |
104,344,646.12 |
112,200,485.23 |
-7.00 |
|
归属于上市公司股东的扣除非经常性损益的净利润 |
98,932,514.65 |
108,827,872.82 |
-9.09 |
|
加权平均净资产收益率(%) |
3.89 |
4.57 |
减少0.68个百分点 |
|
基本每股收益(元/股) |
0.3032 |
0.3260 |
-7.00 |
|
稀释每股收益(元/股) |
0.3032 |
0.3260 |
-7.00 |
非经常性损益项目和金额
单位:元 币种:人民币
|
项目 |
本期金额 |
说明 |
|
非流动资产处置损益 |
-25,888.87 |
|
|
越权审批,或无正式批准文件,或偶发性的税收返还、减免 |
|
|
|
计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外 |
6,648,601.60 |
|
|
委托他人投资或管理资产的损益 |
270,624.68 |
|
|
除上述各项之外的其他营业外收入和支出 |
-166,308.37
|
|
|
少数股东权益影响额(税后) |
-196,583.34 |
|
|
所得税影响额 |
-1,118,314.23 |
|
|
合计 |
5,412,131.47 |
|
2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
单位:股
|
股东总数(户) |
27,298 |
||||||
|
前十名股东持股情况 |
|||||||
|
股东名称(全称) |
期末持股 数量 |
比例(%) |
持有有限售条件股份数量 |
质押或冻结情况 |
股东性质 |
||
|
股份状态 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
16.15 |
0 |
无 |
0 |
国有法人 |
|
|
新余中盛恒兴投资管理合伙企业(有限合伙 |
17,158,922 |
4.99 |
0 |
无 |
0 |
未知 |
|
|
新余汇恒瑞投资管理合伙企业(有限合伙) |
12,665,208 |
3.68 |
0 |
无 |
0 |
未知 |
|
|
香港中央结算有限公司 |
4,372,091 |
1.27 |
0 |
无 |
0 |
未知 |
|
|
刘锦春 |
3,874,269 |
1.13 |
0 |
无 |
0 |
境内自然人 |
|
|
钟以隆 |
3,584,000 |
1.04 |
0 |
无 |
0 |
境内自然人 |
|
|
苏志伟 |
3,226,848 |
0.94 |
0 |
无 |
0 |
境内自然人 |
|
|
王晓红 |
3,121,943 |
0.91 |
0 |
无 |
0 |
境内自然人 |
|
|
骆惠娟 |
2,726,200 |
0.79 |
0 |
无 |
0 |
境内自然人 |
|
|
中国工商银行股份有限公司-南方大数据100指数证券投资基金 |
2,667,200 |
0.78 |
0 |
无 |
0 |
未知 |
|
|
前十名无限售条件股东持股情况 |
|||||||
|
股东名称 |
持有无限售条件流通股的数量 |
股份种类及数量 |
|||||
|
种类 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
人民币普通股 |
55,564,103 |
||||
|
新余中盛恒兴投资管理合伙企业(有限合伙 |
17,158,922 |
人民币普通股 |
17,158,922 |
||||
|
新余汇恒瑞投资管理合伙企业(有限合伙) |
12,665,208 |
人民币普通股 |
12,665,208 |
||||
|
香港中央结算有限公司 |
4,372,091 |
人民币普通股 |
4,372,091 |
||||
|
刘锦春 |
3,874,269 |
人民币普通股 |
3,874,269 |
||||
|
钟以隆 |
3,584,000 |
人民币普通股 |
3,584,000 |
||||
|
苏志伟 |
3,226,848 |
人民币普通股 |
3,226,848 |
||||
|
王晓红 |
3,121,943 |
人民币普通股 |
3,121,943 |
||||
|
骆惠娟 |
2,726,200 |
人民币普通股 |
2,726,200 |
||||
|
中国工商银行股份有限公司-南方大数据100指数证券投资基金 |
2,667,200 |
人民币普通股 |
2,667,200 |
||||
|
上述股东关联关系或一致行动的说明 |
本公司第一大股东通济国投与其他上述第2名至第10名无限售条件股东之间不存在关联关系。公司未知其他9名股东之间是否存在关联关系,也未知是否属于《上市公司收购管理办法》规定的一致行动人。 |
||||||
|
表决权恢复的优先股股东及持股数量的说明 |
不适用 |
||||||
2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情况表
三、 重要事项
3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
|
单位:万元 |
||||
|
资产负债表项目 |
期末数 |
期初数 |
变动幅度 |
变动原因 |
|
预付款项 |
9,726.83 |
4,610.82 |
110.96% |
主要系本报告期子公司预付货款增加所致。 |
|
应收股利 |
2,076.00 |
|
100.00% |
主要系报告期公司按被投资单位天士力控股集团有限公司2017年度利润分配的股东会决议计入应收的现金股利所致。 |
|
其他应收款 |
1,997.52 |
1,308.75 |
52.63% |
主要系报告期公司及子公司存出保证金增加所致。 |
|
其他流动资产 |
925.10 |
1,328.92 |
-30.39% |
主要系报告期子公司抵扣了上年取得的留抵进项税所致。 |
|
短期借款 |
16,800.00 |
8,900.00 |
88.76% |
主要系报告期公司银行贷款增加所致。 |
|
应付职工薪酬 |
1,279.67 |
3,627.55 |
-64.72% |
主要系报告期公司及子公司发放上年末计提的年终奖所致。 |
|
应付利息 |
1,579.21 |
934.17 |
69.05% |
主要系报告期公司计提应付债券利息以及由于银行借款增加相应计提利息增加所致。 |
|
应付股利 |
2,520.16 |
120.16 |
1997.38% |
主要系报告期子公司股东会决议已宣告发放2017年度现金股利所致。 |
|
利润表项目 |
本期数 |
上年同期数 |
变动幅度 |
变动原因 |
|
税金及附加 |
551.67 |
336.88 |
63.76% |
主要系报告期子公司应交税费增加所致。 |
|
销售费用 |
10,678.03 |
4,772.03 |
123.76% |
主要系报告期子公司尖峰药业销售收入的增长和销售模式的调整,公司销售费用中增加了市场推广费和其他支出。 |
|
投资收益 |
1,950.22 |
6,087.10 |
-67.96% |
主要系报告期公司联营投资单位天士力控股集团有限公司利润大幅减少,公司权益法核算计入投资收益相应减少所致。 |
|
其他收益 |
502.73 |
0.00 |
100.00% |
主要系本报告期公司按新会计准则要求将与公司日常活动有关的政府补助从“营业外收入”科目转入所致。 |
|
营业外收入 |
171.06 |
485.84 |
-64.79% |
主要系本报告期公司按新会计准则要求将与公司日常活动有关的政府补助转入“其他收益”项目所致。 |
|
营业外支出 |
27.23 |
4.66 |
483.87% |
主要系报告期子公司营业外支出增加所致。 |
|
所得税费用 |
3,098.44 |
1,981.63 |
56.36% |
主要系本报告期子公司实现的利润总额增加相应的所得税费用增加所致。 |
|
现金流量表项目 |
|
|
|
|
|
经营活动产生的现金流量净额 |
1,396.72 |
31.78 |
4295.58% |
主要系报告期由于公司经营活动现金流入增加所致。 |
|
投资活动产生的现金流量净额 |
-9,823.08 |
-2,287.17 |
|
主要系报告期子公司对外投资及在建项目投入增加所致。 |
|
筹资活动产生的现金流量净额 |
7,779.59 |
-210.06 |
|
主要系报告期公司增加了银行借款所致。 |
3.2 重要事项进展情况及其影响和解决方案的分析说明
1、2017年2月28日,公司九届10次董事会通过了《关于子公司对外投资的议案》,公司控股子公司尖峰药业拟以增资和股权转让的方式分期对北慧生物进行投资;2018年3月31日,公司披露了对外投资进展情况。上述事项详见2017年3月1日、2018年3月31日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2017-003《关于子公司对外投资的公告》、临2018-003《关于子公司对外投资的进展公告》。
2、2018年1月19日,本公司十届2次董事会通过了《关于子公司尖峰药业对外投资的议案》,尖峰药业拟投资11132.79万元以收购股份和增资的方式对上海北卡进行投资。投资完成后,上海北卡注册资本由原来的1100万元增加至1755.55万元,其中尖峰药业占55%。上述事项详见2018年1月20日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-002《关于子公司尖峰药业对外投资的公告》。截止报告期末,尖峰药业已经按照协议约定,支付了第一期股权转让款和增资款。目前正在办理资产交接、工商变更登记手续。
3、2017年4月15日,公司九届11次董事会通过了《关于尖峰国贸新建仓库(电商物流园)项目的议案》,批准控股子公司尖峰国贸投资7500万元新建仓库(电商物流园)。2017年6月6日,公司九届13次董事会通过了《关于尖峰国贸仓库出租的议案》,同意尖峰国贸将该新建仓库(电商物流园)的仓库、堆场、停车场等物业出租给上海安能聚创供应链管理有限公司。上述事项详见2017年4月18日、2017年6月7日披露于上海证券交易所网站(http//:www.sse.com.cn/) 的临2017-006《九届11次董事会决议公告》和临2017-013《九届13次董事会决议公告》。截止3月底,该项目累计已投入资金3909.65万元。
3.3 报告期内超期未履行完毕的承诺事项
3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警示及原因说明
|
公司名称 |
浙江尖峰集团股份有限公司 |
|
法定代表人 |
蒋晓萌 |
|
日期 |
2018年4月27日 |
- 发布时间: 2018-04-28
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11